{"url_path":"/sec/cgem/8-k/2026-05-18/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-18","source_url":"https://www.sec.gov/Archives/edgar/data/1789972/0001193125-26-229173-index.html","accession_number":"0001193125-26-229173","cik":"0001789972","ticker":"CGEM","issuer_name":"Cullinan Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1789972/0001193125-26-229173-index.html","primary_entity_key":"0001789972","primary_entity_name":"Cullinan Therapeutics, Inc."},"word_count":170,"has_tables":true,"body_markdown":"## Item 7.01 Regulation FD Disclosure.\n\nOn May 18, 2026, Cullinan Therapeutics, Inc. (the “Company”) issued a press release announcing that the Company will present initial clinical data from its Phase 1 OUTRACE Program for CLN-978 in patients with treatment-refractory rheumatoid arthritis (“RA”) and treatment-refractory moderate to severe systemic lupus erythematosus (“SLE”) at the European Alliance of Associations for Rheumatology European Congress of Rheumatology (“EULAR”) in June. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.\n\nThe information in this report furnished pursuant to Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing."}